白蛋白可对抗晚期肝病患者脂质介质的免疫抑制作用
研究分析45例急性加重或慢加急性肝衰竭且血清白蛋白低于30 g/L患者的血样,这些患者在一项20%人血白蛋白溶液输注的可行性研究中输注后血清白蛋白升至30 g/L及以上。结果显示输注后患者血浆可逆转健康巨噬细胞的免疫抑制,白蛋白与前列腺素E2结合增加,但介质水平未变;作者提出基于脂质谱分类炎症反应的方法,并认为需随机对照试验确定白蛋白输注是否减少感染。
要点
- 基线时急性加重或慢加急性肝衰竭患者血浆诱导健康巨噬细胞产生肿瘤坏死因子显著低于健康人血浆(P < .0001)。
- 输注20%人血白蛋白溶液后患者血浆诱导巨噬细胞产生肿瘤坏死因子显著高于输注前(19.5 ± 4.8 ng/mL vs 17.7 ± 4.5 ng/mL,P = .0013)。
- 患者血浆蛋白与前列腺素E2结合比例显著低于对照(61.9% vs 77.1%,P = .0012),输注后较基线平均增加8.7%(P < .0001)。
核心结论
- 在20%人血白蛋白溶液输注可行性研究中,将血清白蛋白提升至30 g/L以上可通过结合并灭活前列腺素E2逆转血浆介导的免疫功能障碍。
- 基于脂质谱分类急性加重或慢加急性肝衰竭炎症反应的方法可能有助于识别最可能对人血白蛋白溶液治疗有反应的患者。
- 需要随机对照试验来确定人血白蛋白溶液的这些效应是否减少急性加重或慢加急性肝衰竭患者的感染。
研究设计与样本
- 分析一项20%人血白蛋白溶液输注效果可行性研究中79例急性加重或慢加急性肝衰竭患者中的45例血样,这些患者血清白蛋白低于30 g/L且输注后血清白蛋白升至30 g/L及以上。
- 通过比较加入血浆样本后巨噬细胞功能测定免疫功能,并同时使用12名健康个体的样本。
- 检测血浆蛋白与前列腺素E2的结合、血清内毒素(脂多糖)和细胞因子水平;使用10例患者样本研究前列腺素E2抑制剂的作用。
- 对10例不同患者人血白蛋白溶液给药前后的样本进行全面的脂质代谢组学分析。
主要发现
- 基线时急性加重或慢加急性肝衰竭患者血浆诱导健康巨噬细胞产生肿瘤坏死因子显著低于健康个体血浆(P < .0001)。
- 人血白蛋白溶液输注后患者血浆诱导巨噬细胞产生肿瘤坏死因子水平为19.5 ± 4.8 ng/mL,显著高于治疗前采集血浆的17.7 ± 4.5 ng/mL(P = .0013)。
- 急性加重或慢加急性肝衰竭患者血浆蛋白(白蛋白)与前列腺素E2结合比例平均为61.9%,显著低于对照血浆的77.1%(P = .0012)。
- 人血白蛋白溶液治疗后患者血浆蛋白与前列腺素E2结合较基线平均增加8.7%(P < .0001)。
- 急性加重或慢加急性肝衰竭患者循环前列腺素E2、脂多糖及炎症或抗炎细胞因子水平高于健康志愿者;人血白蛋白溶液输注对介质水平无影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with acute decompensation and acute-on-chronic liver failure (AD/ACLF) have immune dysfunction, which increases their risk for infections; however, there are no effective treatments to restore their immune function. We investigated whether the potentially immune-restorative effects of albumin are mediated by its effects on prostaglandin E2 (PGE2) and other lipids. METHODS: We analyzed bloods samples from 45 of 79 patients with AD/ACLF and serum levels of albumin less than 30 g/L for whom infusion of 20% human albumin solution (HAS) increased serum levels of albumin 30 g/L or more in a feasibility study of effects of 20% HAS. Immune function was determined by comparison of macrophage function following addition of plasma samples. We also used samples from 12 healthy individuals. We measured binding of plasma proteins to PGE2 and serum levels of endotoxin (lipopolysaccharide) and cytokines; using 10 patients' samples, we investigated the effects of PGE2 inhibitors. We performed a comprehensive lipid metabolomic analysis using samples from 10 different patients, before and after HAS administration. RESULTS: At baseline, AD/ACLF patient plasma induced significantly lower production of tumor necrosis factor by healthy macrophages than plasma from healthy individuals (P < .0001). Plasma from patients after HAS infusion induced significantly higher levels of tumor necrosis factor production by macrophages (19.5 ± 4.8 ng/mL) compared with plasma collected before treatment (17.7 ± 4.5 ng/mL; P = .0013). There was a significantly lower proportion of plasma protein (albumin) binding to PGE2 from patients with AD/ACLF plasma (mean, 61.9%) compared with plasma from control subjects (77.1%; P = .0012). AD/ACLF plasma protein binding to PGE2 increased following HAS treatment compared with baseline (mean increase, 8.7%; P < .0001). Circulating levels of PGE2, lipopolysaccharide, and inflammatory or anti-inflammatory cytokines were higher in patients with AD/ACLF than healthy volunteers. Unexpectedly, HAS infusion had no effect on mediator levels. Principal component analysis of baseline levels of lipids that induce or resolve inflammation identified 2 distinct groups of patients that differed according to baseline plasma level of lipopolysaccharide. Sample analyses after HAS treatment indicated that albumin regulates circulating levels of lipid mediators, but this effect was distinct in each group. CONCLUSIONS: Analysis of blood samples from patients with AD/ACLF participating in a feasibility study of 20% HAS infusions has shown that infusions to raise serum albumin above 30 g/L reversed plasma-mediated immune dysfunction by binding and inactivating PGE2. We also describe a method to classify the inflammatory response in AD/ACLF, based on lipid profile, which could improve identification of patients most likely to respond to HAS treatment. A randomized controlled trial is needed to determine whether these effects of HAS reduce infections in AD/ACLF. Trial registered with European Medicines Agency (EudraCT 2014-002300-24) and adopted by NIHR (ISRCTN14174793).
引用
- China L, Maini A, Skene SS, et al. Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease. Clin Gastroenterol Hepatol. 2017. PMID: 28859868. doi:10.1016/j.cgh.2017.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。